Illumina (NASDAQ:ILMN) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Illumina (NASDAQ:ILMN) posted its quarterly earnings results on Thursday. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10, FiscalAI reports. Illumina had a return on equity of 31.04% and a net margin of 19.57%.During the same period last year, the company posted $0.97 EPS. Illumina’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina updated its FY 2026 guidance to 5.150-5.300 EPS.

Here are the key takeaways from Illumina’s conference call:

• Illumina beat Q1 guidance on revenue, margins, and EPS and raised 2026 guidance to $4.52–$4.62B revenue, non‑GAAP operating margin of 23.4%–23.6%, and EPS of $5.15–$5.30, citing Q1 outperformance.
• Demand for the NovaSeq X accelerated with over 80 placements in Q1 (≈20 more YoY) and sequencing consumables grew, led by clinical consumables which rose ~20% ex‑China and represented >65% of consumables revenue.
• Management said they were supply‑constrained on NovaSeq X units and expect Q2 operating margins near ~22% due to a higher instrument mix, inflationary component/freight costs and a full quarter of SomaLogic, though they expect margin improvement in H2.
• Illumina closed the SomaLogic acquisition (~$363M net), reported the business performing in line with expectations, and the board authorized an additional $1.5B in share repurchases while gross leverage sits around 1.5x LTM EBITDA.

Illumina Trading Up 5.3%

NASDAQ:ILMN traded up $6.37 on Thursday, reaching $126.74. The company’s stock had a trading volume of 2,412,187 shares, compared to its average volume of 1,296,474. Illumina has a 1-year low of $73.86 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm has a market cap of $19.25 billion, a PE ratio of 23.26, a PEG ratio of 2.31 and a beta of 1.49. The business’s 50-day moving average price is $125.68 and its two-hundred day moving average price is $126.43.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Illumina during the 3rd quarter valued at about $32,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Illumina by 975.6% during the 4th quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock valued at $58,000 after purchasing an additional 400 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in shares of Illumina by 93.1% during the fourth quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock worth $73,000 after acquiring an additional 268 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Illumina during the third quarter worth $102,000. Finally, Headlands Technologies LLC bought a new stake in shares of Illumina during the second quarter worth $165,000. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ILMN. Guggenheim raised their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Robert W. Baird set a $137.00 price target on shares of Illumina in a research report on Friday, February 6th. Evercore set a $150.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, TD Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $129.69.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 results beat estimates: Illumina reported non‑GAAP EPS of $1.15 vs. consensus ~$1.05 and revenue of $1.09B (+4.8% y/y), signaling steady top‑line and margin improvement. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Raised FY2026 EPS guidance and revenue range: Company gave FY EPS guidance of $5.150–5.300 (above consensus ~5.12) and revenue guidance slightly above estimates — a signal management expects continued profitability. Illumina lifts 2026 outlook and expands share buybacks
• Positive Sentiment: Large share‑repurchase authorization: Board approved an additional $1.5B in buybacks, which supports EPS and signals capital return priority. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Operational strength: GAAP and non‑GAAP operating margins improved (non‑GAAP operating margin ~21.9%) and ROE is strong, underpinning earnings quality. Illumina Q1 Profit Rises On Higher Revenue, Improved Margins
• Neutral Sentiment: Product/tech update could be a longer‑term catalyst: DRAGEN v4.5 (ML‑powered genomics software) was highlighted as a meaningful upgrade for variant calling and multiomic workflows — positive for positioning but benefits are gradual. Will DRAGEN v4.5’s ML-Powered Genomics Upgrade Reshape Illumina’s (ILMN) Precision Medicine Narrative?
• Neutral Sentiment: Conference call / disclosures: Management provided detailed slides and a transcript that clarify growth drivers and assumptions — useful for modeling but no surprise items were flagged. Listen to Conference Call
• Negative Sentiment: Modest revenue growth: Revenue rose only ~4.8% y/y (ROW organic ~3.5%), underscoring that top‑line expansion remains modest and may limit upside versus higher‑growth biotech peers. Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.